Drugs / BP-C1
BP-C1
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01861509 | Jan 2014 → Jan 2016 | female breast carcinoma | Meabco A/S | Completed | No outcome recorded |
| Phase 1 | NCT04298333 | Jun 2009 → Jan 2011 | breast cancer | Meabco A/S | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT03627390 | Dec 2014 → Mar 2016 | malignant pancreatic neoplasm | Meabco A/S | Completed | No outcome recorded |
| Phase 2 | NCT03603197 | Jun 2014 → Aug 2016 | breast cancer | Meabco A/S | Completed | No outcome recorded |
| Phase 2 | NCT03789019 | Feb 2013 → Jul 2016 | breast cancer | Meabco A/S | Completed | No outcome recorded |
| Phase 2 | NCT02783794 | Dec 2012 → Feb 2014 | breast cancer | Meabco A/S | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BP-C1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04298333 ↗ |
| Known as | benzene-poly-carboxylic acid complex with cis-diammineplatinum(II) dihydrocholride | “A benzene-poly-carboxylic acid complex with cis-diammineplatinum(II) dihydrocholride, BP-C1 is currently used in clinical trials in treating metastatic breast cancer.” PMID 25792808 ↗ Mar 2015 |
| Known as | benzene-poly-carboxylic acids complex with cis-diammineplatinum (II) dichloride | “The aims were to compare the efficacy and tolerability of a new benzene-poly-carboxylic acids complex with cis-diammineplatinum (II) dichloride (BP-C1) versus placebo and to...” PMID 25473312 ↗ Nov 2014 |
| Modality | Other / unclassified | “novel platinum-containing anticancer agent developed for intramuscular administration” NCT03603197 ↗ |
| Route | Intramuscular | “intramuscularly once daily for 32 consecutive days” NCT01861509 ↗ |